Collectively, our results for the first time demonstrate that STOML2 is up-regulated and indicated an unfavorable prognosis in CRC by activating NF-κB signaling pathway and modulating cell proliferation, angiogenesis and immune evasion, which provide a promise for diagnosis and treatment for CRC. The gene discussed is STOML2; the disease is colorectal carcinoma.